We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

59 hedge funds and large institutions have $164M invested in Autolus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $665K

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

3% less capital invested

Capital invested by funds: $169M → $164M (-$5.08M)

3.64% less ownership

Funds ownership: 38.11% → 34.47% (-3.6%)

14% less funds holding

Funds holding: 69 → 59 (-10)

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

Holders
59
Holders Change
-10
Holders Change %
-14.49%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
21
Reduced
15
Closed
20
Calls
$1.22M
Puts
$665K
Net Calls
+$555K
Net Calls Change
+$555K

Top Buyers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
+$7.88M
2
NCM
Nantahala Capital Management
Connecticut
+$7.22M
3
PG
Pendal Group
Australia
+$5.53M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.79M
5
Wells Fargo
Wells Fargo
California
+$698K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$5.12M
2
SCM
Sio Capital Management
New York
-$3.93M
3
Goldman Sachs
Goldman Sachs
New York
-$3.75M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.59M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
51
Group One Trading
Illinois
$14K +$13.3K +2,100 New
PCM
52
Penserra Capital Management
California
$8K +$474 +75 +6%
CFGS
53
Concourse Financial Group Securities
Alabama
$7K – – –
ED
54
Exane Derivatives
France
$1.18K – – –
Osaic Holdings
55
Osaic Holdings
Arizona
$1K – – –
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$1K +$505 +80 +133%
Northwestern Mutual Wealth Management
57
Northwestern Mutual Wealth Management
Wisconsin
$1K +$1.26K +200 New
SCM
58
Sio Capital Management
New York
– -$3.93M -591,870 Closed
Marshall Wace
59
Marshall Wace
United Kingdom
– -$1.98M -297,749 Closed
Alyeska Investment Group
60
Alyeska Investment Group
Illinois
– -$1.39M -208,706 Closed
VF
61
Virtu Financial
New York
– -$863K -129,907 Closed
Allianz Asset Management
62
Allianz Asset Management
Germany
– -$815K -122,680 Closed
JGC
63
J. Goldman & Co
New York
– -$391K -58,870 Closed
TI
64
Trexquant Investment
Connecticut
– -$275K -41,372 Closed
MGIM
65
M&G Investment Management
United Kingdom
– -$264 -37,705 Closed
HF
66
HRT Financial
New York
– -$227K -34,303 Closed
D.E. Shaw & Co
67
D.E. Shaw & Co
New York
– -$216K -32,500 Closed
Jane Street
68
Jane Street
New York
– -$196K -29,588 Closed
DTL
69
Dynamic Technology Lab
Singapore
– -$164K -24,786 Closed
CSS
70
Cubist Systematic Strategies
Connecticut
– -$134K -20,244 Closed
XT
71
XTX Topco
Cayman Islands
– -$101K -15,286 Closed
Deutsche Bank
72
Deutsche Bank
Germany
– -$99K -14,876 Closed
Tudor Investment Corp
73
Tudor Investment Corp
Connecticut
– -$93K -13,991 Closed
PA
74
Parallel Advisors
California
– -$1K -180 Closed
CAPTRUST Financial Advisors
75
CAPTRUST Financial Advisors
North Carolina
– -$1K -160 Closed
1 2
3
4

AUTL Hedge Fund Activity: Q3 2021 in Review

59 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2021, worth a combined $164M — down 3% from $169M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of AUTL and 10 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 21 added.

The largest buyer was Frazier Management, adding an estimated $7.88M. The largest seller was Ikarian Capital, cutting an estimated $5.12M.

  • 59 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $164M of Autolus Therapeutics stock for Q3 2021, down 3% quarter-over-quarter.
  • 10 funds opened new Autolus Therapeutics positions in Q3 2021 and 20 closed out, a net change of -10 holders.
  • The largest Autolus Therapeutics buyer in Q3 2021 was Frazier Management, an estimated $7.88M added.
  • The largest Autolus Therapeutics seller in Q3 2021 was Ikarian Capital, an estimated $5.12M sold.

Based on aggregated 13F filings for Q3 2021.